In the search for blood-based detection of AD biomarkers, a SERS-based sensor has developed for the relative quantitation of tau protein in the plasma of AD patients [65], while the combination of SERS with seed amplification assays (SAAs) offers an intriguing prospect in proteinopathies such as PD and AD [66]. Here, MAPT is linked to Alzheimer disease.